Cited by 16Breast Cancer Treatment StudiesHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments

Open access
Rangarajan, K, Lazzereschi, L, Votano, D, Hamady, Z·2023·The Annals of The Royal College of Surgeons of England

Abstract

Introduction: The current gold standard treatment for breast cancer liver metastases (BCLM) is systemic chemotherapy and/or hormonal therapy. Nonetheless, greater consideration has been given to local therapeutic strategies in recent years. We sought to compare survival outcomes for available systemic and local treatments for BCLM, specifically surgical resection and radiofrequency ablation. Methods: A review of the PubMed (MEDLINE), Embase and Cochrane Library databases was conducted. Data from included studies were extracted and subjected to time-to-event data synthesis, algorithmically reconstructing individual patient-level data from published Kaplan–Meier survival curves. Findings: A total of 54 studies were included, comprising data for 5,430 patients (surgery, n=2,063; ablation, n=305; chemotherapy, n=3,062). Analysis of the reconstructed data demonstrated survival rates at 1, 3 and 5 years of 90%, 65.9% and 53%, respectively, for the surgical group, 83%, 49% and 35% for the ablation group and 53%, 24% and 14% for the chemotherapy group (p<0.0001). Conclusion: Local therapeutic interventions such as liver resection and radiofrequency ablation are effective treatments for BCLM, particularly in patients with metastatic disease localised to the liver. Although the data from this review support surgical resection for BCLM, further prospective studies for managing oligometastatic breast cancer disease are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1308/rcsann.2021.0308

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 2

  1. Bacalbasa N, 2014, Anticancer Res, 34, 5563
  2. Abbas S, 2011, ISRN Oncol, 2011, 763245

Cited by

Sorted by citations

See all 16

Metadata

Authors
Rangarajan, K., Lazzereschi, L., Votano, D., & Hamady, Z.
Affiliations
  • University Hospital Southampton NHS Foundation Trust (GB)
  • Ashford and St Peter's Hospitals NHS Foundation Trust (GB)
Venue
The Annals of The Royal College of Surgeons of England
Published
2023-04
Volume
105
Issue
4
Pages
293-305
ISSN
  • 0035-8843 (ISSN-L)
  • 1478-7083
OpenAlex
W4213266198
Cited by
16
References
69
Citations by year
2026: 6 · 2025: 5 · 2024: 3 · 2023: 1
FWCI
0.30
Type
journal article
Language
en
Open access
Locations
  • Annals of The Royal College of Surgeons of England (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
breast cancer liver metastasis, hepatectomy, radiofrequency ablation, systemic chemotherapy, hormone therapy, survival outcomes, local therapy, oligometastatic disease
MeSH terms
Melanoma, Cutaneous Malignant, Cutaneous Malignant Melanoma, Breast Neoplasms, Female, Hepatectomy, Humans, Liver Neoplasms, Prospective Studies, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments. https://app.cochat.ai/papers/10.1308/rcsann.2021.0308
The paper
Rangarajan, K., Lazzereschi, L., Votano, D., & Hamady, Z. (2023). Breast cancer liver metastases: systematic review and time to event meta-analysis with comparison between available treatments. The Annals of The Royal College of Surgeons of England. https://doi.org/10.1308/rcsann.2021.0308